The Melatonin Receptor Agonist Ramelteon Induces Cardioprotection that Requires MT2 Receptor Activation and Release of Reactive Oxygen Species
Open Access
- 31 March 2020
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 34 (3) , 303-310
Abstract
Purpose: The melatonin receptor (MT) agonist ramelteon has a higher affinity to MT1 than for MT2 receptors and induces cardioprotection by involvement of mitochondrial potassium channels. Activation of mitochondrial potassium channels leads to release of free radicals. We investigated whether (1) ramelteon-induced cardioprotection is MT2 receptor specific and (2) if free radicals are involved in ramelteon-induced cardioprotection.Methods: Hearts of male Wistar rats were randomized, placed on a Langendorff system, and perfused with Krebs-Henseleit buffer at a constant pressure of 80 mmHg. All hearts were subjected to 33 min of global ischemia and 60 min of reperfusion. Before ischemia hearts were perfused with ramelteon (Ram) with or without the MT2 receptor inhibitor 4-phenyl-2-propionamidotetralin (4P-PDOT+Ram, 4P-PDOT). In subsequent experiments, ramelteon was administered together with the radical oxygen species (ROS) scavenger N-2-mercaptopropionylglycine (MPG+Ram). To determine whether the blockade of ramelteon-induced cardioprotection can be restored, we combined ramelteon and MPG with mitochondrial permeability transition pore (mPTP) inhibitor cyclosporine A (CsA) at different time points. Infarct size was determined by triphenyltetrazolium chloride (TTC) staining.Results: Ramelteon-induced infarct size reduction was completely blocked by 4P-PDOT and MPG. Ramelteon and MPG combined with CsA before ischemia were not cardioprotective but CsA at the onset of reperfusion could restore infarct size reduction.Conclusions: This study shows for the first time that despite the higher affinity to MT1 receptors, (1) ramelteon-induced cardioprotection involves MT2 receptors, (2) cardioprotection requires ROS release, and (3) inhibition of the mPTP can restore infarct size reduction.Keywords
Funding Information
- Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
This publication has 27 references indexed in Scilit:
- Milrinone-Induced Pharmacological Preconditioning in Cardioprotection: Hints for a Role of Mitochondrial MechanismsJournal of Clinical Medicine, 2019
- Guidelines for experimental models of myocardial ischemia and infarctionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2018
- Morphine-Induced Preconditioning: Involvement of Protein Kinase A and Mitochondrial Permeability Transition PorePLOS ONE, 2016
- Effect of Cyclosporine on Left Ventricular Remodeling After Reperfused Myocardial InfarctionJACC, 2010
- Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial InfarctionNew England Journal of Medicine, 2008
- Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition poreBritish Journal of Anaesthesia, 2008
- Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonistNeuropharmacology, 2005
- Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolalityAmerican Journal of Physiology-Heart and Circulatory Physiology, 2000
- Progression of Myocardial Necrosis During Reperfusion of Ischemic MyocardiumCirculation, 1998
- Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.Circulation, 1986